Abstract
Two neurokinin-3 receptor (NK3r) antagonists, osanetant and talnetant, have recently shown positive results in clinical trials for schizophrenia. Following these disclosures, research has accelerated significantly. This review focuses on progress for NK3r antagonists since 2004, primarily from the patent literature. The emphasis here is on NK3r antagonists as treatments for schizophrenia. In addition, antagonists of NK3r that have efficacy at NK1r and/or NK2r have also been explored as antipsychotics or as treatments for other psychiatric disorders and these will be included in this review.
Keywords::